1. Introduction {#sec1}
===============

*Staphylococcus aureus* is one of the major causes of hospital and community acquired infections that can vary from mild superficial lesions to acute deep and systemic infections. Increasing antimicrobial resistance in *Staphylococcus aureus* has led to major concerns about the future of antimicrobial therapy of its infections. Finding methicillin resistant *Staphylococcus aureus* (MRSA) strains, just two years after the clinical use of betalactamase resistant betalactams, put specialists into trouble with treating these infections. About twenty years later in 1980s, alternative effective anti-Staphylococcal antibiotics such as vancomycin were introduced \[[@B1], [@B2]\]. Thence, for many years vancomycin was the drug of choice for MRSA infections, until the first *S. aureus* isolate with reduced sensitivity to vancomycin (vancomycin intermediate *Staphylococcus aureus* (VISA)) was reported in Japan in 1997 \[[@B3]\]. Thereafter, several reports of VISA from USA \[[@B4]\], France \[[@B5]\], Brazil \[[@B6]\], Korea \[[@B7]\], and other parts of the world \[[@B8]\] were published and resulted in increasing concerns about the effectiveness of vancomycin therapy in serious Staphylococcal infections. Reduced sensitivity to vancomycin in *S. aureus* occurs due to several genetic and phenotypic alterations in wild-type bacteria including altered expression of regulatory genetic elements, thickness of cell wall, changes in the penicillin binding protein (PBP) profiles, and decreased cell wall autolysis \[[@B9]\]. Since 2002, there have been also several reports of vancomycin resistant *Staphylococcus aureus* (VRSA) strains, mainly from the United States, India, and Iran \[[@B10]--[@B19]\]. The majority of the reported VISA isolates are MRSA strains with reduced susceptibility to vancomycin even though a few reports have also shown this phenomenon in methicillin sensitive *Staphylococcus aureus* (MSSA) isolates \[[@B9], [@B20]--[@B22]\]. Data obtained from genetic analysis of VISA isolates was rarely reported in Asian countries, particularly from Iran. Here, we reported genetic characteristics of five VISA strains, isolated from admitted patients in three teaching hospitals in Isfahan, Mashhad, and Tehran, Iran, in the autumn of 2011.

2. Methodology {#sec2}
==============

171 isolates of *Staphylococcus aureus* were obtained from patients admitted between September 23 2011 and December 21 2011 at selected hospitals in Isfahan, Mashhad, and Tehran, Iran.

These isolates were taken from blood, urine, sputum, wound, abscess, nose, throat, eye, and respiratory tract samples. *S. aureus* isolates were identified by conventional biochemical tests including gram staining, catalase, mannitol fermentation, slide, and tube coagulase test and DNase.

2.1. Screening for Methicillin and Vancomycin Resistance {#sec2.1}
--------------------------------------------------------

All *S. aureus* isolates were screened for oxacillin and vancomycin resistance using agar screening method. The isolates that had grown in vancomycin agar screening media were retested with phenotypic tests to confirm the identification. It is noteworthy that the data obtained from *spa* typing, considered to be highly specific for *S. aureus,* was in align with phenotypic data and confirmed the isolated strains as *S. aureus*.

2.2. Antimicrobial Susceptibility Test {#sec2.2}
--------------------------------------

Antibiotic susceptibility test was carried out using disk diffusion method (MAST DISKS) according to guidelines of Clinical Laboratory Standards Institute (CLSI) \[[@B23], [@B24]\]. The list of the antibiotics used in the test is presented in [Table 2](#tab2){ref-type="table"}. Strain of *S. aureus* ATCC 25923 was used as control.

2.3. MIC Determination {#sec2.3}
----------------------

Oxacillin and vancomycin agar dilution was used for all *S. aureus* isolates according to guidelines of Clinical Laboratory Standards Institute (CLSI). *E*-Test method (Biomeriux Strips) was used for redetermination of MIC results for *S. aureus* strains capable of growing in the vancomycin agar screening plate and/or having vancomycin MIC 4--8 *μ*g/mL. Methicillin resistance was defined as the capability of growth in agar screening media including 4% NaCl + 6 *μ*g/mL oxacillin and MIC ≥ 4 *μ*g/mL and vancomycin intermediate resistance was defined as vancomycin MIC of 4--8 *μ*g/mL \[[@B23]\]. Strains of *Staphylococcus aureus* ATCC 29213 and *Enterococcus faecalis*ATCC 52199 were used as controls.

2.4. Genomic DNA Extraction {#sec2.4}
---------------------------

Genomic DNAs of *S. aureus* isolates were extracted using QIAamp DNA minikit. According to manufacturer\'s protocol for bacterial cells, we added lysostaphin at the final concentration of 30 *μ*g/mL in lysis buffer.

2.5. PCR {#sec2.5}
--------

PCR amplification was performed with a TAKARA Gradient PCR TP600 thermal cycler in a volume of 50 *μ*L. We used EmeraldAmp MAX PCR Master Mix (Takara, Japan) for all PCR reactions.

\(i\) PCR Identification of *mecA* and *vanA* GenesThe primers used for amplification of *mecA* and *vanA* genes are listed in [Table 3](#tab3){ref-type="table"}. PCR was performed with the following thermal setting: 5 min at 94°C for initial enzyme activation followed by 40 cycles of amplification (denaturation at 94°C for 30 sec for *mecA* and 1 min for *vanA*; annealing at 57°C for 45 sec for *mecA* and at 55°C for 1 min for *vanA*; extension at 72°C for 30 sec for *mecA* and 2 min for *vanA*) and final extension at 72°C for 5 min.

\(ii\) Multiplex PCR for Detection of Toxin GenesThe primers used for amplification of *Panton-Valentine Leukocidin (pvl), Toxic Shock Syndrome Toxin-1 (tst1), alpha hemolysin* (*hla*), and *Enterotoxin C* (*sec*) genes are listed in [Table 3](#tab3){ref-type="table"}. PCR was performed with the following thermal setting: 5 min at 94°C for initial enzyme activation followed by 40 cycles of amplification (denaturation at 94°C for 40 sec; annealing at 60°C for 40 sec; extension at 72°C for 1 min) and final extension at 72°C for 5 min.

\(iii\) Multiplex PCR for *SCCmec* and *agr* Typing*SCCmec* and *agr* typing were performed as previously described \[[@B25], [@B26]\]. The primers used for the PCR are listed in [Table 3](#tab3){ref-type="table"}.

2.6. MLST {#sec2.6}
---------

Multilocus Sequence Typing was carried out by PCR and sequencing of the internal fragments of *arc*, *aro*, *glp*, *gmk*, *pta*, *tpi*, and *yqi genes of S. aureus* as previously described \[[@B27]\].

2.7. *spa* Typing {#sec2.7}
-----------------

Determination of *spa* type was performed by PCR and sequencing of polymorphic X region of *spa* gene was carried out as previously described \[[@B28]\].

2.8. Nucleotide Sequencing {#sec2.8}
--------------------------

Amplified PCR products were purified with QIAquick Gel Extraction Kit. The purified PCR products were sequenced with an ABI 3730XL DNA analyzer (Applied Biosystems) in both directions. The sequences were used for both confirmation and sequence-based typing methods (MLST and *spa* typing).

3. Results {#sec3}
==========

Of 171 *S. aureus* isolates analyzed, we found that 115 isolates (67%) were MRSA and 5 isolates (2.9%) showed intermediate resistance to vancomycin. The demographic data and antibiogram results of these strains are listed in [Table 2](#tab2){ref-type="table"}. Moreover, genetic evaluation results including *mecA* and *vanA* genes PCR, *Sccmec* types, *agr* groups, toxin profiles, *spa* types and Sequence Types (STs) are presented in [Table 1](#tab1){ref-type="table"}.

4. Discussion {#sec4}
=============

Isolation of VISA strains has been reported in many parts of the world. Resistance to vancomycin has led to global concerns owing to the fact that vancomycin is considered as the last effective drug of choice for Staphylococcal infections \[[@B3]--[@B8]\]. The isolation of heteroresistant VISA (hVISA) and VISA strains has been increasingly reported from different Asian countries with various prevalence rates \[[@B3], [@B7], [@B29], [@B30]\]. There are not many reports concerning the prevalence rate of VISA strains in Iran; however, in 2008, Saderi et al. reported the mean prevalence rate of 1.8% for VISA isolated from clinical samples based on evaluation of four teaching hospitals in Tehran \[[@B31]\]. In our study, we found five VISA strains (2.9%) amongst 171 *S. aureus* isolates. Our data shows an upward trend in the isolation of VISA strains in Iran that might be due to the high and uncontrolled vancomycin prescription rate, even though more research is needed to elucidate the matter.

Some reports have been published concerning the antimicrobial susceptibility patterns of VISA strains, isolated in various parts of the world \[[@B32], [@B33]\]. In most of these studies, the majority of the isolates were resistant to clindamycin but were susceptible to most of the other anti-Staphylococcal antibiotics \[[@B34]--[@B36]\]. Most of VISA strains in this study were also resistant to clindamycin. In contrast, Levofloxacin, Ciprofloxacin, Cotrimoxazole, and Gentamycin were effective on most of the VISA isolates ([Table 2](#tab2){ref-type="table"}).

The majority of the previously reported VISA strains were resistant to methicillin; however, there have been also a few reports about methicillin sensitive *Staphylococcus aureus*-VISA (MSSA-VISA) strains \[[@B9]\]. Two isolates of our five VISA strains, both obtained from the same hospital in Mashhad, were susceptible to methicillin; however, one of them was isolated from throat sample of a hospitalized patient in internal ward and another was isolated from wound sample of an outpatient in urgent ward that had not had any history of hospitalization. With regard to genetic characteristics, the two strains were similar; for instance, both of them belonged to *agr* group II and sequence type 8 (ST8) and therefore, clonal complex 8 (CC8). However, their *spa* types and toxin profiles were different. The wound isolated strain (VISA4) had *spa* type t008 and was positive for *Panton-Valentine Leukocidin* (*pvl*) and *alpha Hemolysin* (*hla*) genes. On the other hand, the throat isolated strain (VISA5) belonged to *spa* type t0189 and merely had *Toxic Shock Syndrome Toxin* (*tst1*) gene. Owing to the fact that sequence type is considered as a long-term and stable epidemiological marker over time and due to full homology in the sequence type of the two isolates, we deduced that they might have a common ancestor. On the other hand, alterations in some genes, such as *spa*and virulence factor genes, might be due to the fact that these elements are more prone to genetic alterations in a shorter period of time.

The relation between *agr* group, type of infection, geographical area, and resistance to some antibiotics, particularly vancomycin, is highlighted in some articles \[[@B38]\]. Impaired function of accessory gene regulator (*agr*) has been associated with the development of VISA strains \[[@B9]\]. *agr* I or II is associated with VISA strains isolated from diverse geographical regions \[[@B32], [@B33], [@B38], [@B39]\]. Our findings are in concordance with these reports. Both of our MSSA-VISA strains belonged to *agr* II but the other three MRSA-VISA strains had *agr* I.

All the patients with MRSA-VISA either had a previous history of hospitalization or were being hospitalized at the time of sampling. Moreover, their *SCCmec* types belonged to types I and III. Collectively, the data indicates that the isolated MRSA-VISA strains were hospital-acquired MRSA (HA-MRSA). VISA1 strain was positive for all evaluated toxin genes including *pvl*, *hla*, *sec,* and *tst1* which can increase its potential pathogenicity; however, this isolate was susceptible to most of the tested antibiotic disks ([Table 2](#tab2){ref-type="table"}). Interestingly, *pvl* gene was found in HA-MRSA "VISA1" despite the fact that it is mostly found in CA-MRSA strains. VISA 2, 3 did not have any major toxin genes.

All of our MRSA-VISA isolates (two isolates from Isfahan in center of Iran and one isolate from Mashhad in northeast of Iran) had *spa* t037 and their STs were ST1283, ST585, and ST239 for VISA 1, 2, and 3, respectively. ST1283 and ST585 are single-locus variants (SLV) of ST239, the endemic strain of Asia ([Figure 1](#fig1){ref-type="fig"}) which our data suggest to be the probable common ancestor of our MRSA-VISA isolates. All of our five VISA isolates belonged to clonal complex 8 (CC8) that is the major endemic *S. aureus* clone (particularly MRSA) in Asia and also is one of the pandemic MRSA clones \[[@B33], [@B40]--[@B45]\].

Increasing antibiotic resistance in major *S. aureus* clones intensifies precautionary policies for public health care systems. In this study, we have shown the upward trend of MSSA- and MRSA-VISA clones in Iran. Moreover, findings of our study suggest that the isolated VISA strains most probably belong to endemic Asian clones. In addition, these data suggest that vancomycin resistance has the potential to become a widespread problem in both MRSA and MSSA strains.
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###### 

Genetic characteristics of VISA isolates.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------
          *agr*   *Sccmec*   *pvl*   *hla*   *etc*   *ts1t*   *mecA*   *vanA*   *spa* type   *spa* repeat profile            ST        CC   MLST allelic profile
  ------- ------- ---------- ------- ------- ------- -------- -------- -------- ------------ ------------------------------- --------- ---- ----------------------
  VISA1   I       III        \+      \+      \+      \+       \+       −        t037         15-12-16-02-25-17-24            ST-1283   8\   2-3-1-88-4-4-3

  VISA2   I       I          −       \+      −       −        \+       −        t037         15-12-16-02-25-17-24            ST-585    8    2-1-1-1-4-4-3

  VISA3   I       III        −       \+      −       −        \+       −        t037         15-12-16-02-25-17-24            ST-239    8    2-3-1-1-4-4-3

  VISA4   II      −          \+      \+      −       −        −        −        t008         11-19-12-21-17-34-24-34-22-25   ST-8      8    3-3-1-1-4-4-3

  VISA5   II      −          −       −       −       \+       −        −        t0189        07-23-12-21-17-34               ST-8      8    3-3-1-1-4-4-3
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------

*pvl*: Panton-Valentin Leukocidin, *sec*: Enterotoxin C, *tst1*: Toxic Shock Syndrome Toxin1, *hla*: alpha Hemolysin, *agr*: accessory gene regulator, *SCCmec*: Staphylococcal Cassette Chromosome, *spa*: Staphylococcal protein A.

###### 

Phenotypic characteristics of VISA isolates.

  ------------------------------------------------------------------------------------------------------------------------------------------------------
          Gender/age   city      Sample/ward          Oxa   Van\   Min   Lev   Cip   Tet   Cot   Gen   Cli   Rif   Oxa MIC   Van MIC   Van Agar screen
  ------- ------------ --------- -------------------- ----- ------ ----- ----- ----- ----- ----- ----- ----- ----- --------- --------- -----------------
  VISA1   M/15         Mashhad   Blood/neurology      R     S      S     S     S     R     S     R     S     S     128       8         \+

  VISA2   M/39         Isfahan   Throat/out patient   R     S      S     R     R     R     R     R     R     R     128       4         \+

  VISA3   M/50         Isfahan   Blood/neurology      R     S      R     S     S     S     S     S     R     R     64        4         \+

  VISA4   M/52         Mashhad   Wound/urgent         S     S      R     S     S     S     S     S     R     S     2         4         −

  VISA5   M/71         Mashhad   Throat/Internal      S     S      I     R     R     R     R     S     R     I     2         4         \+
  ------------------------------------------------------------------------------------------------------------------------------------------------------

Oxa: oxacillin, Van: vancomycin, Min: minocyclin, Lev: levofloxacin, Cip: ciprofloxacin, Tet: tetracycline, Cot: cotrimoxazole, Gen: gentamycin, Cli: clindamycin, Rif: rifampicin, R: resistant, S: susceptible.

###### 

Primers used in this study.

  Target       Primer                         Sequence (5′-3′)          Product size (bp)   Reference
  ------------ ------------------------------ ------------------------- ------------------- ------------
  *mecA*       F                              AGAAGATGGTATGTGGAAGTTAG   583                 This study
  R            ATGTATGTGCGATTGTATTGC                                                        
                                                                                            
  *pvl*        F                              GGAAACATTTATTCTGGCTATAC   502                 This study
  R            CTGGATTGAAGTTACCTCTGG                                                        
                                                                                            
  *hla*        F                              CGGTACTACAGATATTGGAAGC    744                 This study
  R            TGGTAATCATCACGAACTCG                                                         
                                                                                            
  *sec*        F                              GGGAATGTTGGATGAAGG        900                 This study
  R            AGGCAAGCACCGAAGTAC                                                           
                                                                                            
  *tst1*       F                              TTATCGTAAGCCCTTTGTTG      398                 This study
  R            TAAAGGTAGTTCTATTGGAGTAGG                                                     
                                                                                            
  *agr*        Pan F                          ATGCACATGGTGCACATGC                           \[[@B26]\]
  R I          GTCACAAGTACTATAAGCTGCGAT       439                                           
  R II         GTATTACTAATTGAAAAGTGCCATAGC    572                                           
  R III        CTGTTGAAAAAGTCAACTAAAAGCTC     406                                           
  R IV         CGATAATGCCGTAATACCCG           657                                           
                                                                                            
  *SCCmec*     F *β*                          ATTGCCTTGATAATAGCCYTCT    937                 \[[@B25]\]
  R *α*3       TAAAGGCATCAATGCACAAACACT                                                     
  F ccrC       CGTCTATTACAAGATGTTAAGGATAAT    518                                           
  R ccrC       CCTTTATAGACTGGATTATTCAAAATAT                                                 
  F 1272       GCCACTCATAACATATGGAA           415                                           
  R 1272       CATCCGAGTGAAACCCAAA                                                          
  F 5R*mecA*   TATACCAAACCCGACAACTAC          359                                           
  R 5R431      CGGCTACAGTGATAACATCC                                                         
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